Hematology Frontier

The 5th Tianjin International Lymphoma Academic Conference, as an academic platform to promote international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and cooperation in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Professor Owen O’Connor, President of the Lymphoma Alliance and from the University of Virginia Cancer Center, and Professor Zhengzi Qian from the Tianjin Medical University Cancer Hospital to engage in a dialogue between China and the rest of the world, reviewing the current status and latest advances in the treatment of relapsed/refractory peripheral T-cell lymphoma (R/R PTCL).

Recently, the 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association was successfully held in Tianjin, attracting hundreds of domestic and international authoritative experts and scholars in the field of hematology. During the conference, "Hematology Frontier" specially invited Dr. Norbert Claude Gorin from Hôpital Saint-Antoine in Paris, a member of the French National Academy of Medicine, and a foreign academician of the Chinese Academy of Engineering, to discuss the evolution of the role of autologous transplantation in the treatment of acute myeloid leukemia (AML) and the challenges and potential of immunotherapy in AML treatment.

Recently, the 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association was successfully held in Tianjin, attracting hundreds of domestic and international authoritative experts and scholars in the field of hematology. During the conference, "Hematology Frontier" specially invited Dr. Salomon Manier from the Hematology Department of Lille University Hospital in France to discuss the current treatment challenges, emerging treatment plans, and management in the elderly and frail patient population for patients with transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM).

Prof. Xiaohui Zhang’s pioneering study marks the first international use of baricitinib for hormone-resistant/relapsed immune thrombocytopenia (ITP). This phase 2 trial with 35 adult patients achieved a 6-month response rate of 57.1% and was well-tolerated, opening new avenues for ITP treatment. The findings were presented at the European Hematology Association and published in the American Journal of Hematology.

Recently, the 11th Sino-French Hematology Academic Conference successfully took place in Tianjin, China, attracting hundreds of top authorities and scholars in the field of hematology from both domestic and international circles. During the conference, "Hematology Frontier" specially invited Dr. Arnaud Pigneux from Haut-Leveque Hospital, University of Bordeaux, to discuss the innovative practice achievements of the French Innovative Leukemia Organization (FILO).

Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, China, attracting hundreds of top experts and scholars in the field of hematology from both China and abroad. During the conference, "Hematology Frontier" specially invited Dr. Christian Chabannon from the Paoli-Calmettes Institute in Marseille, France, to discuss the strategies of personalized immunotherapy from a European perspective.

Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, attracting hundreds of top experts and scholars in the field of hematology from China and abroad. During the conference, Dr. Frédéric Millot from the University Hospital of Poitiers, France, was invited by "Hematology Frontier" to share the future directions in the treatment of chronic myeloid leukemia (CML) in children.

The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lanfang Li from the Tianjin Medical University Cancer Institute and Hospital and Dr. Weiyun Zhuang from the University of California, San Francisco (UCSF) School of Medicine, to engage in a China-International dialogue, reviewing the latest treatment strategies for mycosis fungoides (MF) and Sézary syndrome (SS).

The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lihua Qiu from Tianjin Medical University Cancer Institute and Hospital and Dr. Swaminathan Iyer from The University of Texas MD Anderson Cancer Center to engage in a China-International dialogue, reviewing the latest therapeutic advances in peripheral T-cell lymphoma (PTCL) and the optimization direction of treatment strategies.

From September 25 to September 29, the 27th National Clinical Oncology Conference and CSCO Annual Meeting, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen. During the conference, Hematology Frontier invited Dr. Zhiming Li from Sun Yat-sen University Cancer Center to share his strategies for treating diffuse large B-cell lymphoma (DLBCL).